• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Ocugen, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; June 10, 2024 deadline

    5/13/24 7:44:39 PM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $OCGN alert in real time by email

    Investors can contact the law firm at no cost to learn more about recovering their losses

    ​LOS ANGELES, May 13, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN) investors that a lawsuit was filed on behalf of investors that purchased Ocugen securities.

    Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursuing claims to recover their losses.

    On April 1, 2024, Ocugen filed a Current Report on Form 8-K with the U.S. Securities and Exchange Commission. The report disclosed that Ocugen discovered accounting errors while preparing its financial statements for the year ended December 31, 2023. These errors were related to the application of U.S. GAAP in certain agreements under a collaboration with a business partner. Due to these findings, Ocugen announced that its audited consolidated financial statements for each fiscal year starting January 1, 2020, and its unaudited interim condensed consolidated financial statements for the first three quarters of those years should no longer be relied upon and will be restated. This also applies to associated earnings releases and any communications describing these financial statements. Additionally, Ocugen acknowledged a material weakness in its internal control over financial reporting that persisted during these periods and admitted that its internal controls and disclosure procedures were ineffective as of December 31, 2023.

    Following this announcement, Ocugen's stock price dropped by $0.16 per share, or 10.38%, closing at $1.38 per share on April 2, 2024.

    Please visit our website to review more information and submit your transaction information.

    The Portnoy Law Firm represents investors in pursuing claims caused by corporate wrongdoing. The Firm's founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

    Lesley F. Portnoy, Esq.

    Admitted CA and NY Bar

    [email protected]

    310-692-8883

    www.portnoylaw.com

    Attorney Advertising



    Primary Logo

    Get the next $OCGN alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $OCGN

    DatePrice TargetRatingAnalyst
    10/15/2024$4.00Buy
    Maxim Group
    3/1/2023$3.50Neutral → Buy
    Chardan Capital Markets
    8/23/2022$5.00Buy
    Mizuho
    6/15/2022$8.00Buy
    ROTH Capital
    6/2/2022$4.50Overweight
    Cantor Fitzgerald
    2/28/2022$10.00 → $8.00Buy
    HC Wainwright & Co.
    7/26/2021Outperform
    Noble Capital Markets
    More analyst ratings

    $OCGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group initiated coverage on Ocugen with a new price target

      Maxim Group initiated coverage of Ocugen with a rating of Buy and set a new price target of $4.00

      10/15/24 8:07:55 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ocugen upgraded by Chardan Capital Markets with a new price target

      Chardan Capital Markets upgraded Ocugen from Neutral to Buy and set a new price target of $3.50

      3/1/23 9:04:17 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Mizuho initiated coverage on Ocugen with a new price target

      Mizuho initiated coverage of Ocugen with a rating of Buy and set a new price target of $5.00

      8/23/22 7:19:06 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $OCGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Fernandes Prabhavathi bought $9,095 worth of shares (10,000 units at $0.91) (SEC Form 4)

      4 - Ocugen, Inc. (0001372299) (Issuer)

      12/2/24 4:15:25 PM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Castillo Kirsten bought $22,848 worth of shares (25,000 units at $0.91), increasing direct ownership by 50% to 75,000 units (SEC Form 4)

      4 - Ocugen, Inc. (0001372299) (Issuer)

      11/26/24 4:50:10 PM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $OCGN
    SEC Filings

    See more
    • SEC Form 144 filed by Ocugen Inc.

      144 - Ocugen, Inc. (0001372299) (Subject)

      7/9/25 4:07:35 PM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ocugen Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - Ocugen, Inc. (0001372299) (Filer)

      7/1/25 3:49:38 PM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ocugen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Ocugen, Inc. (0001372299) (Filer)

      6/23/25 8:58:46 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $OCGN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results

      MALVERN, Pa., July 17, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company's second quarter 2025 financial results and provide a business update at 8:30 a.m. ET on Friday, August 1, 2025. Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details: Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international callersConference ID: 9627149Webcast: Available on the events section of the

      7/17/25 6:30:16 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease

      MALVERN, Pa., June 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) amendment to initiate a Phase 2/3 pivotal confirmatory trial of OCU410ST, a modifier gene therapy candidate being developed for all Stargardt disease (ABCA4-associated retinopathies). The FDA previously granted Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation for OCU410ST for the treatment of ABCA4-associated retinopathies including Stargardt disease, retinitis pigmentosa 19, and cone-r

      6/16/25 7:02:34 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ocugen To Present at BIO International Convention 2025

      MALVERN, Pa., June 11, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present at the 2025 BIO International Convention at the Boston Convention & Exhibition Center from June 16-19, 2025. During the conference, Ocugen's leadership team will host meetings with potential partners and pharmaceutical executives to explore opportunities for the Company's novel modifier gene therapy platform targeting major blindness diseases with a one-time therapy for life. "We are excited to return to BIO this year on the heels of our recent execution of a bindin

      6/11/25 7:30:50 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $OCGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: SEC Form 3 filed by new insider Chandrasekhar Satishchandran

      3/A - Ocugen, Inc. (0001372299) (Issuer)

      6/12/25 4:28:45 PM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Chandrasekhar Satishchandran

      4 - Ocugen, Inc. (0001372299) (Issuer)

      6/9/25 5:19:37 PM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Coleman Blaise

      4 - Ocugen, Inc. (0001372299) (Issuer)

      6/9/25 5:19:31 PM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $OCGN
    Financials

    Live finance-specific insights

    See more
    • Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results

      MALVERN, Pa., July 17, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company's second quarter 2025 financial results and provide a business update at 8:30 a.m. ET on Friday, August 1, 2025. Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details: Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international callersConference ID: 9627149Webcast: Available on the events section of the

      7/17/25 6:30:16 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ocugen Provides Business Update with First Quarter 2025 Financial Results

      Conference Call and Webcast Today at 8:30 a.m. ET OCU400 Phase 3 clinical trial for retinitis pigmentosa (RP) is progressing well and on target for potential BLA/MAA filings by mid-2026Anticipate initiating OCU410ST Phase 2/3 pivotal confirmatory clinical trial for Stargardt disease mid- 2025 MALVERN, Pa., May 09, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today reported first quarter 2025 financial results along with a general business update. "All three of our novel modifier gene therapies are advancing through the clinic and we are on track to meet our goal of three Biologic

      5/9/25 8:01:07 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results

      MALVERN, Pa., May 02, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company's first quarter 2025 financial results and provide a business update at 8:30 a.m. ET on Friday, May 9, 2025. Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details: Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international callersConference ID: 1773288Webcast: Available on the events section of the Ocuge

      5/2/25 8:00:37 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $OCGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Ocugen Inc.

      SC 13G/A - Ocugen, Inc. (0001372299) (Subject)

      11/12/24 4:59:47 PM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Ocugen Inc.

      SC 13G/A - Ocugen, Inc. (0001372299) (Subject)

      11/4/24 1:43:41 PM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Ocugen Inc.

      SC 13G - Ocugen, Inc. (0001372299) (Subject)

      10/16/24 12:41:30 PM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $OCGN
    Leadership Updates

    Live Leadership Updates

    See more
    • Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop

      MALVERN, Pa., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-founder of Ocugen, will speak during the workshop titled, "U.S.-India Biotechnology Cooperation: Realizing Benefits, Reducing Risks." This two-day event will take place from September 9-11, 2024 in New Delhi, India. "It is an honor to join the impressive group of thought leaders in this groundbreaking forum," said Dr. Musunuri. "There are endless opportunities to leverage the bes

      9/9/24 6:30:12 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ocugen Set to Join Russell 3000® Index Effective June 28, 2024

      MALVERN, Pa., May 28, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced its expected upcoming inclusion in the Russell 3000® Index, according to preliminary Russell reconstruction information posted on the FTSE Russell website. The newly reconstructed index will take effect after the market closes on June 28, 2024. "Inclusion of Ocugen to the Russell 3000® Index is our latest milestone, adding to what has already been a transformational year for the Company with three of our game-changing modifier gene therapies targeting

      5/28/24 7:02:39 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ocugen, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; June 10, 2024 deadline

      Investors can contact the law firm at no cost to learn more about recovering their losses ​LOS ANGELES, May 13, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN) investors that a lawsuit was filed on behalf of investors that purchased Ocugen securities. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursuing claims to recover their losses. On April 1, 2024, Ocugen filed a Cur

      5/13/24 7:44:39 PM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care